Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP4 | P15090 | 9/20 | 0.47 |
| ▸ | CDC25A | P30304 | 2/20 | 0.41 |
| ▸ | CDC25B | P30305 | 2/20 | 0.41 |
| ▸ | WDR5 | P61964 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5118925 | 0.96 | FABP4 (0.43) | FABP4CDC25ACDC25BWDR5CA1 | |
| SCHEMBL5115200 | 0.82 | FABP4 (0.46) | FABP4CDC25ACDC25BALDH1A1TBXA2R | |
| SCHEMBL3992993 | 0.81 | WDR5 (0.40) | CDC25AWDR5ALDH1A1 | |
| SCHEMBL4464905 | 0.81 | WDR5 (0.39) | FABP4WDR5ALDH1A1TBXA2R | |
| SCHEMBL5117224 | 0.79 | FABP4 (0.51) | FABP4CDC25ACDC25BCA1CA2 | |
| SCHEMBL5111162 | 0.78 | CDC25A (0.45) | FABP4CDC25ACDC25BCA1CA2 | |
| SCHEMBL6763197 | 0.78 | WDR5 (0.40) | WDR5CA1CA2 | |
| SCHEMBL4040824 | 0.76 | BDKRB1 (0.48) | ALDH1A1 | |
| SCHEMBL15577096 | 0.76 | WDR5 (0.37) | WDR5ALDH1A1 | |
| SCHEMBL4027527 | 0.75 | BDKRB1 (0.46) | WDR5ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7361687-B2 | Arylsulphonamide derivatives and methods of preparing | LABORATOIRES FOURNIER SA (FR) | 2008-04-22 | — | — | US | disclosed |
| US-20060084699-A1 | Novel arylsulphonamide derivatives and use thereof as therapeutic agents | LABORATOIRES FOURNIER SA (FR) | 2006-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084699-A1 | Novel arylsulphonamide derivatives and use thereof as therapeutic agents | UGT1A1, UGT2B7, UGT1A6 | FABP4 2346/4885CDC25A 2950/4885CDC25B 2322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.